BAM
ENTA icon

Blueshift Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Blueshift Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,398
Closed -$208K – 665
2022
Q2 		$208K Sell
4,398
-480
-10% -$26.1K 0.03% 569
2022
Q1 		$347K Buy
+4,878
New +$317K 0.03% 565
2019
Q3 		– Sell
-3,205
Closed -$270K – 785
2019
Q2 		$270K Buy
3,205
+582
+22% +$52.4K 0.04% 573
2019
Q1 		$251K Buy
+2,623
New +$235K 0.04% 573

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Blueshift Asset Management's ENTA Position: Q3 2022 in Review

Blueshift Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q3 2022, closing a stake of 4,398 shares — an estimated $208K sold.

Blueshift Asset Management first reported a position in ENTA in Q1 2019 and held it in 4 quarters. The position peaked at $347K in Q1 2022. 159 funds tracked by Wall St. Rank hold ENTA as of Q3 2022.

  • Blueshift Asset Management reported no remaining Enanta Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Blueshift Asset Management sold 4,398 Enanta Pharmaceuticals shares in Q3 2022, an estimated $208K.
  • Blueshift Asset Management first reported a position in Enanta Pharmaceuticals in Q1 2019 and held it in 4 quarters.
  • Blueshift Asset Management's Enanta Pharmaceuticals position peaked at $347K in Q1 2022.
  • 159 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2022.

Based on Blueshift Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.